GHK-Cu Australia: Research Overview

The short answer

GHK-Cu is a small, naturally occurring human tripeptide that binds copper. It is one of the most widely studied copper peptides in laboratory and preclinical research, and the copper tripeptide is also a long-established ingredient in topical cosmetic skincare worldwide. In Australia, GHK-Cu is not recognised as a TGA-approved therapeutic medicine and does not appear on the Australian Register of Therapeutic Goods (ARTG) as an approved injectable medicine.

Topical cosmetic products containing the copper tripeptide are sold in Australia without TGA therapeutic approval, which is a different context from any research-grade or injectable material. Research-grade GHK-Cu supplied by NovaPeptides is provided strictly for laboratory research use only and is not for human or animal use. Anyone needing a definitive legal position should check the current TGA Poisons Standard and seek their own professional advice.

What is GHK-Cu?

GHK-Cu is the copper(II) complex of a tripeptide with the amino acid sequence glycyl-L-histidyl-L-lysine, usually written GHK. In cosmetic ingredient nomenclature the tripeptide is also referred to as copper tripeptide-1. The GHK sequence has a strong affinity for copper ions and readily forms the GHK-Cu complex, which is the form most often discussed in the research literature.

GHK is described in the published literature as a naturally occurring human peptide that is present in human plasma. Research reports note that plasma GHK levels are commonly cited as being higher in younger adults and lower in older adults, an observation frequently repeated in the ageing and tissue-regeneration literature. The peptide was first isolated from human plasma in the 1970s and has been studied for several decades since.

At a glance

• Compound: copper(II) complex of glycyl-L-histidyl-L-lysine (GHK)
• Also known as: copper tripeptide, copper tripeptide-1 (cosmetic nomenclature)
• Origin: a naturally occurring human tripeptide that binds copper
• Research framing: studied largely in vitro and in preclinical models

Structure and copper binding

The interest in GHK centres on its chemistry. The histidine and terminal amine groups within the glycyl-L-histidyl-L-lysine sequence create a coordination environment that binds copper(II) with high affinity. Copper is an essential trace element involved in numerous enzyme systems, and the literature on GHK often frames the peptide as a carrier or modulator of copper at the tissue level rather than as a copper source alone.

Because GHK-Cu is a copper-bound peptide, much of the published research examines how the complex behaves in cell culture and in model systems, including how it may interact with the extracellular matrix and with copper-dependent processes. These are laboratory observations and do not establish any clinical outcome in humans.

Mechanisms studied in research

The published research on GHK-Cu spans several areas of cell and molecular biology. The descriptions below summarise what has been studied in laboratory and preclinical settings. They are not claims that GHK-Cu produces any effect in people and should not be read as therapeutic or cosmetic promises.

Areas explored in the literature

• Copper binding and transport, with GHK acting as a copper-binding ligand in model systems
• Interaction with the extracellular matrix, including studies of collagen and related matrix components in cell culture
• Signalling and gene-expression research, with reports describing modulation of numerous genes in cultured cells
• Antioxidant-related research examining oxidative-stress pathways in skin cell models
• Tissue-remodelling and wound-healing research in preclinical and in vitro settings

It is important to read these as research directions rather than established human benefits. Much of the strongest evidence comes from in vitro work and animal or tissue models, and findings in such systems do not automatically translate to humans.

The state of the evidence

GHK-Cu has an unusually long research history for a small peptide, with a body of literature built up over several decades. However, the bulk of that literature sits at the in vitro and preclinical level, alongside a separate and more applied history as a topical cosmetic ingredient.

The cosmetic-ingredient context is well documented: the copper tripeptide appears in many commercial skincare formulations internationally. That commercial use is distinct from rigorous therapeutic evidence, and it does not amount to regulatory approval of GHK-Cu as a medicine. Where you see strong claims online about outcomes in people, treat them with caution and look for the underlying study design, species and route of administration.

Australian regulatory status

In Australia, therapeutic goods are regulated by the Therapeutic Goods Administration (TGA), and scheduling of substances sits within the Poisons Standard. GHK-Cu is not TGA-approved as a therapeutic medicine and does not have an entry on the ARTG as an approved injectable medicine.

On scheduling, GHK-Cu is not individually scheduled in the Poisons Standard in the same explicit way that some other research peptides are named. The copper tripeptide is commonly present in topical cosmetic products sold in Australia without TGA therapeutic approval. Because scheduling and classification can change, and because the position can depend on the specific product, form and claims made, the current status should always be checked directly against the TGA Poisons Standard and the ARTG rather than assumed.

A key distinction the TGA draws is between cosmetic presentation and therapeutic presentation. A product can shift into the therapeutic category based on the claims made about it or its route of administration. Injectable presentations in particular are treated differently from topical cosmetics. None of this constitutes legal advice, and businesses or individuals should obtain their own regulatory guidance.

What to verify yourself

• Current TGA Poisons Standard scheduling position for the substance
• ARTG status for any specific product or presentation
• Whether any claim being made converts a cosmetic into a therapeutic good
• State and territory requirements that may apply

WADA and sport integrity

Athletes subject to anti-doping rules should not assume that an absence from the named prohibited list means a substance is permitted. As at the latest available information, GHK-Cu is not specifically named on the WADA Prohibited List. However, WADA maintains a broad category covering certain pharmacological substances that have no current approval by a government regulatory health authority for human therapeutic use, and substances can be caught by that broad wording.

Because of that broad language, GHK-Cu can sit in a grey area for tested athletes. Anyone competing under anti-doping rules in Australia should confirm their specific situation with Sport Integrity Australia and the current WADA documents before making any decision.

Research use and supply

Research-grade GHK-Cu supplied by NovaPeptides is provided strictly for laboratory research use only. It is not a medicine, not a cosmetic product and not intended for human or animal use. This is a deliberate and important distinction from the topical cosmetic context, where the copper tripeptide appears as a formulated skincare ingredient.

If you are a researcher, handling, storage and documentation should follow good laboratory practice and your institution's requirements. If you are a consumer interested in the copper tripeptide for skincare, that is an entirely separate retail cosmetic category and is outside the scope of research-grade supply.